

AMENDMENT No. 1

Partnership Agreement number: T0010000788 = Targeted and improved Alzheimer's Disease Drug Development (TARIMAD)

The parties agree to amend the Partnership Agreement as follows ('Amendment'):

1. Changes of Attachment 5 (Partnership budget)

Attachment 5 is changed and replaced by the Partnership budget attached to this Amendment. All other provisions of the Partnership Agreement and its Annexes remain unchanged.

2. Change in legal form of Project Partner 3, Bioinova

Since June 3 2021, Project Partner 3 is registered as a joint stock company, no longer as a limited liability company (společnost s ručením omezeným in Czech).

This Amendment enters into force on the day of the last signature.

This Amendment takes effect on the date on which the amendment has been published in the register of contracts.

SIGNATURES

Fakultní nemocnice Hradec Králové, Project Promoter

Date: 15-05-2021
fbb" (767/A-2021)

Signature: [Redacted]
Name: [Redacted]
Title: [Redacted]

FAKULTNÍ NEMOCNICE
ředitelství
500 05 HRADEC KRÁLOVÉ

I acknowledge that I have read and agree to be bound by the the above terms and conditions and I undertake to ensure that all personnel working in the Project will be aware of and accept all terms and conditions of this Partnership Agreement.

Date: [Redacted]
Signature: [Redacted]
Name: Assoc.
Title: Princip

University of Oslo, Project Partner 1

Date: 24.06.2021

Signature: [Redacted]

Name: [Redacted]

Title: Head of Administration, Institute of Clinical Medicine [Redacted]

UNIVERSITY OF OSLO
FACULTY OF MEDICINE
Institute of clinical medicine
P.O. Box 1171 Blindern, NO-0318 Oslo
NORWAY

I acknowledge that I have read and agree to be bound by the above terms and conditions and I undertake to ensure that all personnel working in the Project will be aware of and accept all terms and conditions of this Partnership Agreement.

Date: 24.6.2021 [Redacted]

Signature: [Redacted]

Name: [Redacted]

Title: Principal Investigator

Ústav experimentální medicíny AV ČR, v. v. i., Project Partner 2

Date: 24. 6. 2021
Signature: [Redacted]
Name: [Redacted]
Title: Director


I acknowledge that I have read and agree to be bound by the above terms and conditions and I undertake to ensure that all personnel working in the Project will be aware of and accept all terms and conditions of this Partnership Agreement.

Date: 24. 6. 2021
Signature: [Redacted]
Name: [Redacted]
Title: Principal Investigator

Biorivaya, s.r.o., Project Partner 3

Date: _____

Signature: _____

Name: 

Title: Director

I acknowledge that I have read and agree to be bound by the above terms and conditions and I undertake to ensure that all personnel working in the Project will be aware of and accept all terms and conditions of this Partnership Agreement.

Date: _____

Signature: _____

Name: 

Title: Principal Investigator

BioNova, a.s., Project Partner 3

Date: 23.0.2021
Signature: [Redacted]
Name: [Redacted]

Title: Chairman of the Board of Directors

Date: 16.01.2021
Signature: [Redacted]
Name: [Redacted]

Title: Member of the Board of Directors

I acknowledge that I have read and agree to be bound by the above terms and conditions and I undertake to ensure that all personnel working in the Project will be aware of and accept all terms and conditions of this Partnership Agreement.

Date: 22.01.2021
Signature: [Redacted]
Name: [Redacted]

Title: Principal Investigator

[Attachment 5: Partnership Budget]

Partnership Budget (Budget breakdown) (CZK)

Project Promoter - Fakultní nemocnice Hradec Králové					
Item/Year	2021	2022	2023	2024	Celkem
Personel Costs	1 997 202	2 085 494	1 674 811	3 278 577	6 036 084
Subcontracting	0	0	0	0	0
Other Direct Costs	236 092	286 048	260 508	196 658	979 306
Other Indirect Costs	558 330	592 885	483 830	131 122	1 766 167
Total Costs	2 791 624	2 964 427	2 419 149	655 637	8 830 837
Financial Contribution	2 791 624	2 964 427	2 419 149	655 637	8 830 837
Indirect eligible costs determined as					Flat rate 25%

Partner 1 - University of Oslo					
Item/Year	2021	2022	2023	2024	Celkem
Personel Costs	2 144 338	2 191 331	2 225 555	700 817	7 262 041
Subcontracting	0	0	0	0	0
Other Direct Costs	1 088 004	1 169 732	1 335 742	837 712	4 431 190
Other Indirect Costs****	808 086	840 266	890 324	384 632	2 923 308
Total Costs	4 040 428	4 201 330	4 451 622	1 923 162	14 616 542
Financial Contribution	4 040 428	4 201 330	4 451 622	1 923 162	14 616 542
Indirect eligible costs determined as					Flat rate 25%

Partner 2 - ÚJEM					
Item/Year	2021	2022	2023	2024	Celkem
Personel Costs	983 673	983 673	983 673	327 883	3 278 902
Subcontracting	0	0	0	0	0
Other Direct Costs	414 693	492 003	536 340	229 860	1 672 896
Other Indirect Costs	349 591	368 925	379 984	139 423	1 237 923
Total Costs	1 747 957	1 844 601	1 899 997	697 166	6 189 721
Financial Contribution	1 747 957	1 844 601	1 899 997	697 166	6 189 721
Indirect eligible costs determined as					Flat rate 25%

Partner 3 - Bioimova					
Item/Year	2021	2022	2023	2024	Celkem
Personel Costs	1 045 837	1 045 837	1 018 229	492 360	3 602 263
Subcontracting	0	0	0	0	0

Other Direct Costs	416 225	600 190	855 590	472 490	2 344 495
Other Indirect Costs	365 528	411 500	468 455	241 212	1 486 695
Total Costs	1 827 590	2 057 527	2 342 274	1 206 062	7 433 453
Financial Contribution	1 370 680	1 543 126	1 756 692	904 550	5 575 048
Indirect eligible costs determined as	Flat rate 25%				

	FKHR	Jméno	Podpis
Číslo účtu	právní		
	spřítelenský		
	odpovědný pracovník		